Angiotensin II receptor blocker plus angiotensin-converting enzyme inhibitor increases risk for adverse effects

Granger, Christopher B.
March 2008
ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p9
Academic Journal
The article focuses on four trials investigating if the combination of an angiotensin II receptor blocker (ARB) and an angiotensin-converting enzyme inhibitor (ACE-I) increases risk for adverse effects more than standard therapy in symptomatic left ventricular (LV) dysfunction patients. In patients with chronic heart failure or acute myocardial infarction with symptomatic LV dysfunction, the combination of an ARB and an ACE-I increases risk for adverse effects more than standard therapy.


Related Articles

  • Stem Cells for Myocardial Regeneration. Penn, M. S.; Dong, F.; Klein, S.; Mayorga, M. E. // Clinical Pharmacology & Therapeutics;Oct2011, Vol. 90 Issue 4, p499 

    The field of cardiovascular regenerative medicine has made significant strides over the past decade. Clinical trials have demonstrated benefit in acute myocardial infarction (AMI) and chronic heart failure (CHF). As the field has matured, it has defined novel biology and invented an array of...

  • Treatment of heart failure. Mead, Mike // Practice Nurse;5/14/2004, Vol. 27 Issue 9, p44 

    Highlights clinical trials that provided the evidence base for diagnosis and therapy for heart failure. Percentage of the population affected by heart failure; Data on the Studies of Left Ventricular Dysfunction trial using angiotensin converting enzyme inhibitors; Benefits using angiotensin...

  • Perindopril attenuates post-MI remodeling.  // Formulary;Oct2005, Vol. 40 Issue 10, p342 

    Reports that the ACE inhibitor perindropil has significantly reduced left ventricular remodeling in a well-treated population of older patients with acute myocardial infarction and preserved ejection fraction. Perindropil Remodeling in Elderly with Acute Myocardial Infarction study led by...

  • ACE inhibitors versus ARBs: comparison of practice guidelines and treatment selection considerations. Miller, Amy E.; Cziraky, Mark; Spinler, Sarah A. // Formulary;Jun2006, Vol. 41 Issue 6, p274 

    Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptors blockers (ARBs) play a role in the treatment of hypertension (HTN) and heart failure (HF). The literature shows that in patients with HTN with comorbidities, such as HF, myocardial infarction (MI), diabetes mellitus,...

  • Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 3: Angiotensin-converting-enzyme inhibitors. Wright, James M. // CMAJ: Canadian Medical Association Journal;8/08/2000, Vol. 163 Issue 3, p293 

    Abstract Elevated blood pressure is associated with an increased risk of cardiovascular illness and death. Efforts to reduce that risk have led to recommendations for a wide array of nondrug and drug therapies. Choosing the optimal first-line drug for hypertensive patients should address a...

  • Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Kiernan, Michael S.; Wentworth, Deborah; Francis, Gary; Martinez, Felipe A.; Dickstein, Kenneth; Komajda, Michel; Zannad, Faiez; Neaton, James D.; Konstam, Marvin A. // European Journal of Heart Failure;Dec2012, Vol. 14 Issue 12, p1401 

    Aims In patients with heart failure and reduced left ventricular ejection fraction (HFrEF), renin–angiotensin–aldosterone system blockade reduces morbidity and mortality, but comes at an increased risk of adverse events (AEs). We utilized the HEAAL trial data to identify predictors...

  • Guideline for the Management of Heart Failure Caused by Systolic Dysfunction: Part II.  // American Family Physician;9/15/2001, Vol. 64 Issue 6, p1045 

    Several large clinical trials conducted over the past decade have shown that pharmacologic interventions can dramatically reduce the morbidity and mortality associated with heart failure. These trials have modified and enhanced the therapeutic paradigm for heart failure and extended treatment...

  • Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart Attack.  // Biomedical Market Newsletter;7/7/2012, Vol. 21, p1 

    The article offers information related to the clinical trial report of Prochymal, stem cell drug, from Osiris Therapeutics Inc. indicated for treatment of patients with first time acute myocardial infarction. It informs that the trial is the largest study of allogeneic or "off-the-shelf" stem...

  • ACE INHIBITOR INTOLERANCE. Kleinschmidt, Debra // Clinical Advisor;Jan2010, Vol. 13 Issue 1, p45 

    The article focuses on the appropriateness to use the angiotensin II receptor blocker (ARB) after thoroughly assessing the patient's level of heart failure in the U.S. The use of ARB has been recommended to substitute the angiotensin-converting enzyme (ACE) inhibitor for patients at risk of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics